Hansa Biopharma AB (publ)

OM:HNSA Stok Raporu

Piyasa değeri: SEK 2.1b

Hansa Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Hansa Biopharma CEO'su Søren Tulstrup, Mar2018 tarihinde atandı, in görev süresi 6.67 yıldır. in toplam yıllık tazminatı SEK 27.51M olup, şirket hissesi ve opsiyonları dahil olmak üzere 30.7% maaş ve 69.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.085% ine doğrudan sahiptir ve bu hisseler SEK 1.81M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 3.5 yıldır.

Anahtar bilgiler

Søren Tulstrup

İcra Kurulu Başkanı

SEK 27.5m

Toplam tazminat

CEO maaş yüzdesi30.7%
CEO görev süresi6.7yrs
CEO sahipliği0.08%
Yönetim ortalama görev süresi4.8yrs
Yönetim Kurulu ortalama görev süresi3.5yrs

Son yönetim güncellemeleri

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21
Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Recent updates

It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Nov 07
It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Oct 20
Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Aug 24
Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%

Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Jul 23
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%

Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Jul 21
Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Jun 21
Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package

Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

May 21
Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump

Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Apr 05
Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates

Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Feb 07
Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report

Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Dec 28
Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing

Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Oct 13
Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts

Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Sep 22
Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?

Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

May 31
Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)

Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Apr 03
Rock star Growth Puts Hansa Biopharma (STO:HNSA) In A Position To Use Debt

Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Feb 06
Hansa Biopharma AB (publ) (STO:HNSA) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

Feb 01
Need To Know: The Consensus Just Cut Its Hansa Biopharma AB (publ) (STO:HNSA) Estimates For 2023

CEO Tazminat Analizi

Søren Tulstrup'un ücretlendirmesi Hansa Biopharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-SEK 655m

Jun 30 2024n/an/a

-SEK 802m

Mar 31 2024n/an/a

-SEK 845m

Dec 31 2023SEK 28mSEK 8m

-SEK 832m

Sep 30 2023n/an/a

-SEK 856m

Jun 30 2023n/an/a

-SEK 759m

Mar 31 2023n/an/a

-SEK 678m

Dec 31 2022SEK 26mSEK 8m

-SEK 611m

Sep 30 2022n/an/a

-SEK 626m

Jun 30 2022n/an/a

-SEK 620m

Mar 31 2022n/an/a

-SEK 583m

Dec 31 2021SEK 26mSEK 7m

-SEK 548m

Sep 30 2021n/an/a

-SEK 491m

Jun 30 2021n/an/a

-SEK 465m

Mar 31 2021n/an/a

-SEK 431m

Dec 31 2020SEK 21mSEK 6m

-SEK 421m

Sep 30 2020n/an/a

-SEK 426m

Jun 30 2020n/an/a

-SEK 398m

Mar 31 2020n/an/a

-SEK 381m

Dec 31 2019SEK 11mSEK 5m

-SEK 360m

Sep 30 2019n/an/a

-SEK 330m

Jun 30 2019n/an/a

-SEK 298m

Mar 31 2019n/an/a

-SEK 274m

Dec 31 2018SEK 8mSEK 4m

-SEK 248m

Tazminat ve Piyasa: Søren 'nin toplam tazminatı ($USD 2.50M ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 467.89K ).

Tazminat ve Kazançlar: Søren şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Søren Tulstrup (59 yo)

6.7yrs

Görev süresi

SEK 27,505,000

Tazminat

Mr. Søren Tulstrup, M.Sc, has been President and Chief Executive Officer of Hansa Biopharma AB (publ) (formerly known as Hansa Medical AB (publ)) since March 20, 2018. Mr. Tulstrup served as the Chief Exec...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Søren Tulstrup
President & CEO6.7yrsSEK 27.51m0.085%
SEK 1.8m
C. Ballantyne
Chief Financial Officerless than a yearVeri yokVeri yok
Christian Kjellman
Senior VP & COO4.8yrsVeri yokVeri yok
Hitto Kaufmann
Chief Scientific and R&D Officerless than a yearVeri yokVeri yok
Eva-Maria Joed
Vice President of Finance & Administration5.5yrsVeri yokVeri yok
Klaus Sindahl
VP & Head of Investor Relationsno dataVeri yokVeri yok
Anne Lanner
Senior VP & Chief Human Resources Officer5.8yrsVeri yokVeri yok
Emanuel Björne
VP & Head of Business Developmentno dataVeri yokVeri yok
Lena Winstedt
Head of Scienceno dataVeri yokVeri yok
Vincenza Nigro
VP & Head of Medical Affairsno dataVeri yokVeri yok
Magnus Korsgren
VP & Head of Research and Development3.6yrsVeri yokVeri yok

4.8yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: HNSA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Florian Nicolas Reinaud
Directorless than a yearVeri yokVeri yok
Anders Pedersen
Independent Director6.5yrsSEK 413.00k0.0037%
SEK 78.8k
Mats Blom
Independent Director5.5yrsSEK 493.00k0.0015%
SEK 31.4k
Peter Nicklin
Independent Chairman of the Board2.4yrsSEK 1.14m0.036%
SEK 771.8k
Eva Nilsagard
Independent Director5.5yrsSEK 591.00k0.0044%
SEK 94.4k
Hilary Malone
Independent Director3.5yrsSEK 725.00kVeri yok
Gunnar Tufveson
Chairman of European Medical Advisory Board in Transplantationno dataVeri yokVeri yok
Kathryn Wood
Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantationno dataVeri yokVeri yok
Christophe Legendre
Member of European Medical Advisory Board in Transplantationno dataVeri yokVeri yok
Stanley Jordan
Chairman of US Medical Advisory Board in Transplantationno dataVeri yokVeri yok
Robert Montgomery
Member of US Medical Advisory Board in Transplantationno dataVeri yokVeri yok
Jonas Wikstrom
Directorless than a yearVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: HNSA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).